Altrius Capital Management Inc Acquires 14,690 Shares of Bristol-Myers Squibb (NYSE:BMY)

Altrius Capital Management Inc lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 27.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,832 shares of the biopharmaceutical company’s stock after purchasing an additional 14,690 shares during the period. Altrius Capital Management Inc’s holdings in Bristol-Myers Squibb were worth $3,532,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Adell Harriman & Carpenter Inc. lifted its position in shares of Bristol-Myers Squibb by 11.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 5,870 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 625 shares in the last quarter. Mid American Wealth Advisory Group Inc. lifted its position in shares of Bristol-Myers Squibb by 10.2% during the fourth quarter. Mid American Wealth Advisory Group Inc. now owns 83,155 shares of the biopharmaceutical company’s stock worth $4,050,000 after purchasing an additional 7,688 shares in the last quarter. Choreo LLC lifted its position in shares of Bristol-Myers Squibb by 2.9% during the fourth quarter. Choreo LLC now owns 88,442 shares of the biopharmaceutical company’s stock worth $4,538,000 after purchasing an additional 2,492 shares in the last quarter. Mather Group LLC. lifted its position in shares of Bristol-Myers Squibb by 7.1% during the fourth quarter. Mather Group LLC. now owns 25,721 shares of the biopharmaceutical company’s stock worth $1,320,000 after purchasing an additional 1,696 shares in the last quarter. Finally, Eagle Wealth Strategies LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $201,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

BMY stock traded down $0.21 during trading hours on Monday, reaching $44.64. The stock had a trading volume of 16,416,463 shares, compared to its average volume of 15,973,770. The stock has a market capitalization of $90.49 billion, a PE ratio of -14.41, a price-to-earnings-growth ratio of 15.47 and a beta of 0.39. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The stock has a 50-day simple moving average of $51.03 and a 200 day simple moving average of $51.10. Bristol-Myers Squibb has a fifty-two week low of $44.34 and a fifty-two week high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 EPS. Analysts predict that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.38%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company increased their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Barclays lowered their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Finally, Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.